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Association of variants in HTRA1 and NOTCH3
with MRI-defined extremes of cerebral small
vessel disease in older subjects
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We report a composite extreme phenotype design using distribution of white matter hyperintensities and brain infarcts in a
population-based cohort of older persons for gene-mapping of cerebral small vessel disease. We demonstrate its application in
the 3C-Dijon whole exome sequencing (WES) study (n = 1924, nWESextremes = 512), with both single variant and gene-based asso-
ciation tests. We used other population-based cohort studies participating in the CHARGE consortium for replication, using whole
exome sequencing (nWES = 2,868, nWESextremes = 956) and genome-wide genotypes (nGW = 9924, nGWextremes = 3308). We restricted
our study to candidate genes known to harbour mutations for Mendelian small vessel disease: NOTCH3, HTRA1, COL4A1,
COL4A2 and TREX1. We identified significant associations of a common intronic variant in HTRA1, rs2293871 using single
variant association testing (Pdiscovery = 8.21  105, Preplication = 5.25  103, Pcombined = 4.72  105) and of NOTCH3 using gene-
based tests (Pdiscovery = 1.61  102, Preplication = 3.99  102, Pcombined = 5.31  103). Follow-up analysis identified significant
association of rs2293871 with small vessel ischaemic stroke, and two blood expression quantitative trait loci of HTRA1 in linkage
disequilibrium. Additionally, we identified two participants in the 3C-Dijon cohort (0.4%) carrying heterozygote genotypes at
known pathogenic variants for familial small vessel disease within NOTCH3 and HTRA1. In conclusion, our proof-of-concept
study provides strong evidence that using a novel composite MRI-derived phenotype for extremes of small vessel disease can
facilitate the identification of genetic variants underlying small vessel disease, both common variants and those with rare and low
frequency. The findings demonstrate shared mechanisms and a continuum between genes underlying Mendelian small vessel disease
and those contributing to the common, multifactorial form of the disease.
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Introduction
Cerebral small vessel disease (SVD) encompasses a group of
pathological processes affecting small arteries, arterioles, capil-
laries and small veins in the brain. It is associated with cog-
nitive impairment, mood disorders, dysfunction of gait and
balance, and with increased risk of stroke, dementia and
death (Pantoni, 2010). Specific mechanistic treatments for
SVD are yet to be identified. Identifying genes underlying
SVD may provide important insight on pathways driving
this disease and accelerate the discovery of novel drug targets.
SVD is driven by a complex mix of environmental and genetic
risk factors (Longstreth, 2005) and both familial and sporadic
conditions of the disease have been reported. Mutations in the
NOTCH3, HTRA1, COL4A1, COL4A2 and TREX1 genes
are known to cause rare familial forms of SVD (Joutel et al.,
1997; Richards et al., 2007; Vahedi et al., 2007; Hara et al.,
2009; Gunda et al., 2014) but endeavours to detect genetic
risk factors for the common multifactorial form of SVD are
still at a preliminary stage. Studies on multiple complex dis-
orders including a few reports on SVD have suggested that
genes harbouring mutations leading to the Mendelian form of
the disease may also harbour polymorphisms leading to the
sporadic condition (Schmidt et al., 2011; Rannikmae et al.,
2015; Stitziel et al., 2015; Fuchsberger et al., 2016).
MRI markers of vascular brain injury, including burden of
white matter hyperintensities (WMH) and small subcortical
infarcts, namely lacunes of presumed vascular origin (here-
after referred to as lacunes), have been shown to reflect pri-
marily SVD and are commonly used for its diagnosis and
assessment of severity (Wardlaw et al., 2013). These MRI
markers are heritable with reported heritability estimates
ranging between 49% and 80% for WMH burden, and
29% for lacunes (Turner et al., 2004; DeStefano et al.,
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2009; Sachdev et al., 2013). To date, genome-wide associ-
ation studies (GWAS) reported five WMH burden risk loci
that explain only a small proportion of its heritable compo-
nent (Fornage et al., 2011; Verhaaren et al., 2015), whereas
no robust genetic association with lacunes has been
described. The extreme-phenotype design was shown to be
a more powerful strategy to identify rare risk alleles under-
lying complex traits (Peloso et al., 2016). Moreover, using a
composite extreme phenotype derived from two key MRI
markers of SVD may increase the phenotype specificity
and reduce misclassification bias that may arise when study-
ing individual MRI-markers, as a ‘control’ without lacunes
may for instance well have extensive WMH burden reflect-
ing underlying SVD (Traylor et al., 2015).
Whole exome sequencing (WES) allows a comprehensive
survey of both rare and common variants in coding regions
and has been helpful in deciphering the genetic architecture
of complex diseases (Cruchaga et al., 2014; Lange et al.,
2014). Here, we report the first WES study on MRI mar-
kers of SVD using a composite extreme phenotype study
design, and focus our exploration on genes harbouring mu-
tations causing Mendelian forms of SVD.
Materials and methods
Study population
The Three City Dijon (3C-Dijon) study is a population-based
cohort of 4931 French non-institutionalized individuals aged
65 years and older (3C Study Group, 2003). A total of 2763
individuals aged 480 years were invited to undergo a brain
MRI between June 1999 and September 2000. Participation
rate was high (83%, n = 2285) but because of financial restric-
tions, only 1924 MRI scans were performed. Among the 1924
participants with MRI data, 1683 had also undergone
genome-wide genotyping. After exclusion of individuals with
brain tumours (n = 8), stroke (n = 71), or dementia (n = 7) at
baseline, the remaining sample comprised 1497 participants
with automated WMH volume measurement.
The Ethical Committee of the University Hospital of
Kremlin-Biceˆtre approved the study protocol. All participants
signed an informed consent to participate in the study.
Brain MRI
MRI acquisition was performed with a 1.5 T Magnetom scan-
ner (Siemens,) using T1-weighted, T2-weighted, and proton
density-weighted sequences, according to the same protocol
at both baseline and follow-up (Kaffashian et al., 2014).
Fully automated image processing software was developed to
detect and localize WMH and to measure WMH volume
(Maillard et al., 2008). Infarcts were rated on T1-, T2- and
proton density-weighted images by the same examiner
(Y.-C.Z.), using a standardized assessment grid, to visually
review all brain scans. Lacunes were defined as infarcts 3–
15mm in diameter having the same signal characteristics as
cerebrospinal fluid on all sequences, located in basal ganglia,
brainstem or cerebral white matter. Characteristics of lesions
were visualized simultaneously in axial, coronal, and sagittal
planes to discriminate them from dilated perivascular spaces.
Lesions with a typical vascular shape and following the
orientation of perforating vessels were regarded as dilated
perivascular spaces (Zhu et al., 2010). The nomenclature of
MRI markers of SVD in our study is consistent with the re-
cently proposed neuroimaging standards for research into SVD
(STRIVE) (Wardlaw et al., 2013; Kaffashian et al., 2014).
Definition of extreme cerebral small
vessel disease
The composite extreme phenotype was defined based on the
distribution of WMH volume and presence or absence of
lacunes in the 3C-Dijon study using 1497 participants from
the 3C-Dijon study who had both MRI scan and GWAS
data. The objective was to define a group with extensive SVD
severity (individuals in the upper quartile of WMH distribution
and having one or more brain infarcts) and a group with min-
imal SVD severity (lower quartile of WMH distribution and
without any brain infarcts). We log-transformed WMH
volume (natural log of [WMH volume in cm3 + 1]) and ex-
tracted residuals adjusted for age, gender, and white matter
mask volume, hereafter referred to as WMH-burden residuals.
The first and fourth quartiles of these residuals were taken to
represent small and large WMH volume, respectively. The 261
participants with extensive SVD were defined from 374 partici-
pants within the fourth quartile of WMH-burden residuals dis-
tribution by including all participants who also had at least one
lacune (n = 58) and by selecting additionally 203 participants
with the highest WMH-burden residuals within the fourth quar-
tile. Similarly, the 253 participants with minimal SVD were
defined from 374 participants within the first quartile of
WMH-burden residuals distribution by the absence of MRI-
defined brain infarcts and having WMH burden residuals at
the bottom tail of the WMH burden residual distribution. The
design used for defining extreme SVD is summarized in Fig. 1.
Covariates and clinical events
At baseline, socio-demographics, medical history, and drug use
data were collected at home during an interview by trained
psychologists. Centralized measurements of fasting plasma glu-
cose, serum total cholesterol, high density lipoprotein choles-
terol, and triglycerides were performed using enzymatic
methods by the Biochemistry Laboratory of the University
Hospital of Dijon. Low density lipoprotein (LDL) cholesterol
was calculated with the Friedewald formula (Friedewald et al.,
1972). Body mass index (BMI) was defined as the ratio of
weight (kg) to the square of height (m). Smoking status was
categorized as never, former, and current. Diabetes mellitus
was defined as intake of antidiabetic drugs or fasting blood
glucose57mmol/l. Hypertension was defined by systolic
blood pressure (BP) 5140mm Hg, or diastolic BP 590mm
Hg, or antihypertensive drug intake. History of cardiovascular
disease was defined by history of myocardial infarction, bypass
cardiac surgery, angioplasty, or peripheral vascular disease.
Hypercholesterolaemia was defined as fasting total cholesterol
56.2mmol/l or use of any lipid-lowering drug. Information
concerning stroke occurrence over time was collected at each
follow-up. Incident stroke was defined as a new focal
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neurological deficit of sudden or rapid onset, of presumed vas-
cular origin, that persisted for 424 h, or leading to death. An
expert panel of neurologists adjudicated diagnosis of stroke
based on criteria of the WHO (1988). Dementia status was
evaluated prospectively by an expert panel using a three-step
procedure (Schilling et al., 2017): (i) participants underwent
neuropsychological evaluations carried out by trained psych-
ologists; (ii) an examination by a neurologist for those who
screened positive at step 1 based on the MMSE and the Isaacs’
Set Test; and (iii) an independent committee of neurologists
Figure 2 NOTCH3 protein modifying rare and low frequency variants in the 3C-Dijon extreme SVD cohort.
Figure 1 Schematic representation of the extreme SVD design in the 3C-Dijon study.
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and geriatricians reviewed all suspected prevalent and incident
dementia cases to reach consensus on the diagnosis and aeti-
ology according to the DSM-IV criteria, using all available
information (e.g. cognitive functioning, severity of cognitive
disorders, hospitalization records when possible, computed
tomography scans, MRI, functional assessments).
Exome sequencing and quality
control
The DNA samples of 514 participants (261 with extensive SVD
and 253 with minimal SVD) with the extremes of SVD severity
underwent high depth WES. The majority of samples (n = 508)
were sequenced at the McGill Genome Center, Montreal,
Canada, and remaining six participants were sequenced at the
Centre National de Ge´notypage, Paris, France. The Agilent
SureSelect Human All Exome V5 exome capture kit was used
for exome capture except for five samples for which the Agilent
SureSelect Human All Exome V4 or V5+UTR exome capture
kits were used. The Illumina HiSeq2000 instrument was used to
perform paired-end sequencing (2  100 bp). The reads were
aligned to the GRCh37 human reference genome sequence
using the software Burrows-Wheeler Aligner and duplicate
reads were tagged with Picard MarkDuplicates (Li and Durbin,
2009). The Genome Analysis Toolkit (GATK) software was used
to perform realignment around InDels and base quality score
recalibration (BQSR) (McKenna et al., 2010). Single-sample call-
ing was performed using HaplotypeCaller from GATK 3.3 in
GVCF mode with base-pair resolution, except 15 samples,
whose calling was generated with default band definition as
part of the Alzheimer Disease Exome Sequencing-France
(ADSP-FR) project (Bellenguez et al., 2017). Calling was done
on the target intervals of each exome kit using a padding of
100bp. Multi-sample calling was performed with the
GenotypeGVCFs tool implemented in GATK 3.4, together with
other samples from the ADES-FR project. Our whole exome
sequence data covered 17649 RefSeq genes with an average
depth of coverage of 80 (Supplementary Fig. 1). We filtered
out samples with missingness 420%, and individuals with 46
standard deviations (SD) for number of singletons, heterozygote
to homozygote ratio, mean depth, and transition to transversion
(Ti/Tv) ratio. This protocol resulted in filtering out two partici-
pants with extensive SVD because of high number of singletons
and low mean depth coverage. We filtered out genotypes with
Phred-scaled confidence for genotype call 520 or average depth
of coverage 58 . In our study, we included only biallelic vari-
ants [(single nucleotide polymorphism (SNPs) and insertions/de-
letions (Indels)]. Additionally, we filtered out variants with mean
depth higher than 500-fold, missingness 420%, and Hardy
Weinberg equilibrium P-value5 5  106. Overall, we achieved
high quality WES data for 259 extensive SVD and 253 minimal
SVD participants (n = 512).
Description of the study sample
Baseline characteristics of participants with extensive SVD and
participants with minimal SVD were compared using analysis
of covariance for continuous variables and chi-square test for
categorical variables. After verifying the proportional hazard
assumption through Schoenfeld residuals, we examined the as-
sociation of extreme SVD and 12-year incident dementia using
Cox proportional regression with age as the time scale, ad-
justed for sex and education status. For incident stroke, we
used the Cox model with age as a timescale and adjusted for
sex, BMI, smoking status, diabetes mellitus, hypertension, his-
tory of cardiovascular disease, and hypercholesterolaemia.
Genetic association tests
We performed single-variant and gene-based tests using the R
package SeqMeta (https://cran.r-project.org/web/packages/
seqMeta/index.html). The primary association models were ad-
justed for age, sex and the first four principal components of
population stratification. In secondary analyses, we addition-
ally adjusted for hypertension status.
Single variant association tests
We performed single variant association tests considering
common and low frequency variants [minor allele frequency
(MAF) 40.01] located within 100 kb of the 50 and 30 UTR of
five candidate genes: NOTCH3, HTRA1, COL4A1, COL4A2
and TREX1. The 100kb arbitrary boundary was considered
to capture cis regulatory variants that might be localized
within neighbouring genes. We used a permutation approach
to derive the significance threshold correcting for multiple as-
sociation tests for 389 common and low frequency variants
that might be in linkage disequilibrium (Supplementary mater-
ial, part A). Additionally we performed the top-SNP associ-
ation tests implemented in the VEGAS2 software (Mishra
and Macgregor, 2015) to account for number of variants
and linkage disequilibrium structure in the locus.
Gene-based analysis
To increase power for association testing of rare and low fre-
quency variants (MAF5 0.05), we also performed gene-based
association tests focusing on five candidate genes: NOTCH3,
HTRA1, COL4A1, COL4A2 and TREX1. We used the vari-
ant effect predictor (v90) software (McLaren et al., 2016) to
annotate functional consequences of genetic variants localized
within five candidate genes considering the default ‘GRCh37’
ensemble annotation database. We used ‘filter_vep’ module to
extract variants with the following functional consequences:
splice acceptor variant, splice donor variant, start lost, stop
lost, stop gained, frameshift variant, inframe insertion, inframe
deletion, and missense variant, to perform gene-based associ-
ation tests on protein-modifying variants only. We used the
SKAT-O approach (Lee et al., 2012) for gene-based analyses
of protein-modifying rare and low frequency variants. We con-
sidered genes with a cumulative MAF of rare or low frequency
protein-modifying variants higher than 1%. We performed
power calculations for SKAT-O test using the R package
SKAT (Wu et al., 2011).
Replication of significant associations
We sought replication of non-exonic significant findings in
genome-wide genotyped subsets imputed to the Haplotype
Reference Consortium (HRC) panel and of exonic variants
in WES subsets of the Atherosclerosis Risk in Communities
(ARIC) study, the Cardiovascular Health study (CHS), the
Framingham Heart study (FHS) and the Rotterdam study, all
participating in the Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE) consortium. The ARIC
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study and the CHS analysed European and African ancestry
samples separately; the FHS and the Rotterdam study analysed
only European ancestry samples. The MRI measurements of
WMH burden and lacunes in these cohorts are described in
the Supplementary material, part B, which also provides details
on quality control of genotyped and WES datasets of these
studies. The extreme SVD phenotype in the replication cohorts
was defined using the same strategy as described above for the
3C-Dijon cohort. We defined one-third of the total sample
with phenotype and genotype information as having ex-
treme-SVD (extensive SVD for one-sixth of the sample, with
extensive WMH burden with or without lacunes, and minimal
SVD for another sixth of the sample with minimal WMH
burden and no brain infarcts). In the FHS and Rotterdam
study, WMH burden residuals were computed using auto-
mated quantitative WMH volume measures adjusting for
age, gender, and intracranial volume, whereas in the ARIC
study and CHS WMH burden residuals were derived from
visual semi-quantitative WMH burden measures adjusting for
age and gender, as intracranial volume was accounted for in
WMH burden assessment. In the FHS, WMH burden residuals
were additionally adjusted for family structure. We separately
defined extreme SVD in genotyped and WES subsets of indi-
vidual studies (see Supplementary Tables 2 and 3, respectively,
for population characteristics of extreme SVD cohorts of gen-
otyped and WES subsets of the ARIC, CHS, FHS and
Rotterdam studies). Of those participants with MRI SVD
phenotype data, the total sample size with genome-wide geno-
types was 9924 for European ancestry participants, of whom
3308 had extreme SVD (n = 1654 with extensive SVD and
n = 1654 with minimal SVD) and 1170 for African ancestry
participants, of whom 390 had extreme SVD (n = 195 with
extensive SVD and n = 195 with minimal SVD). The total
sample size with WES was 2877 for European ancestry par-
ticipants, of whom 956 had extreme SVD (n = 480 with exten-
sive SVD and n = 477 with minimal SVD) and 726 for African
ancestry participants, of whom 242 had extreme SVD (n = 121
with extensive SVD and n = 121 with minimal SVD).
In the ARIC, CHS and Rotterdam studies, the single variant
association tests were performed with an additive model in R
using logistic regression, whereas in the FHS, a generalized
estimation equation was used to account for family structure.
Analyses were adjusted for age, sex and the first four principal
components of population stratification. We used METAL
software (Willer et al., 2010) to perform an inverse variance
weighted meta-analysis of association statistics across replica-
tion cohorts, and with the discovery study.
We used seqMeta software to perform the SKAT-O gene-
based analysis across all replication cohorts. We then meta-
analysed the SKAT-O P-values from discovery and replication
cohorts using Stouffer’s method for sample size weighted com-
bination of p-values.
Association of extreme small vessel
disease risk variants with related
phenotypes
We also tested for association of extreme SVD associated
common variants with stroke and continuous measures of
WMH, in previously reported GWASs of small vessel ischae-
mic stroke [NINDS Stroke Genetics Network (SiGN) and
International Stroke Genetics Consortium (ISGC), 2016]
[defined using the Causative Classification of Stroke (CCS)
system] by the National Institute of Neurological Disorders
and Stroke and the Stroke Genetics Network (NINDS-SiGN)
and of WMH burden (Verhaaren et al., 2015). The GWAS
summary statistics on small vessel ischaemic stroke by the
NINDS-SiGN consortium were accessed using the
Cerebrovascular Disease Knowledge Portal (Crawford et al.,
2018).
We additionally performed SKAT-O gene-based analysis of
protein-modifying rare and low frequency variants observed
within a NOTCH3 targeted Sanger sequenced subsample of
the Austrian Stroke Prevention Study (ASPS) (n = 277) cohort.
Of these 24 participants were filtered out due to missing in-
formation on principal components of population stratifica-
tion, leaving 171 participants with either coalescent white
matter lesions or lacunes and 82 randomly selected partici-
pants with no focal changes on magnetic resonance images
(Schmidt et al., 2011) for the follow-up analysis. The SKAT-
O gene-based analysis was adjusted for age, sex and the first
four principal components of population stratification.
In silico functional exploration of
non-exonic variants
We used the HaploReg (Ward and Kellis, 2012) (version 4.1)
software to perform functional annotation of non-exonic vari-
ants that are in linkage disequilibrium (r240.6 in the 1000
Genomes European panel) with the lead SNP associated with
extreme SVD. We also manually explored expression quanti-
tative trait locus (eQTL) databases: the GTeX database (Mele
et al., 2015) and the blood eQTL resource (Westra et al.,
2013).
NOTCH3 glycosylation site
prediction
NOTCH3 functions are regulated by different types of O-gly-
cosylation of the EGF repeat (EGFr) domain including O-
fucose (Moloney et al., 2000), O-glucose (Moloney et al.,
2000), O-GlcNAc (N-acetylglucosamine) (Matsuura et al.,
2008), O-xylose (Takeuchi et al., 2011) and mucin-type O-
GalNAc (Boskovski et al., 2013). O-fucosylation is mediated
by proteins O-fucosyltransferase 1 and Fringe. Cerebral auto-
somal dominant arteriopathy with subcortical infarcts and leu-
koencephalopathy (CADASIL)-causing mutations were
reported to affect carbohydrate chain elongation of
NOTCH3 by Fringe proteins (Arboleda-Velasquez et al.,
2005). We investigated whether rare and low frequency mis-
sense variants in the NOTCH3 EGFr domain observed in the
3C-Dijon cohort localized at these computationally predicted
mucin-type O-GalNAc glycosylation sites, using the publicly
available software for mucin-type O-GalNAc sites prediction
(Steentoft et al., 2013).
Survey of pathogenic variants
We manually surveyed the ClinVar database (Landrum et al.,
2016) (accessed on 27 February 2017, Supplementary Table 7)
to identify participants in the 3C-Dijon cohort carrying a rare
allele at SVD causing pathogenic or likely pathogenic
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mutations in the following genes: NOTCH3 (Joutel et al.,
1997) [causing CADASIL (OMIM:125310)], HTRA1 (Hara
et al., 2009) [causing cerebral autosomal recessive arteriopathy
with subcortical infarcts and leukoencephalopathy (CARASIL,
OMIM:600142)], COL4A1 (Vahedi et al., 2007) [causing
COL4A1-related familial vascular leukoencephalopathy
(OMIM:607595); and pontine autosomal dominant microan-
giopathy with leukoencephalopathy (PADMAL), porence-
phaly-1 (OMIM:175780)], COL4A2 (Gunda et al., 2014)
[causing porencephaly-2 (OMIM: 614483)], and TREX1
(Richards et al., 2007) [causing retinal vasculopathy and cere-
bral leukodystrophy (RVCL, OMIM:192315)].
In addition to the pathogenic and likely pathogenic variants
classified in the ClinVar database, we systematically searched
for NOTCH3 EGFr domain cysteine-modifying missense vari-
ants, the typical type of mutation causing CADASIL (Rutten
et al., 2016b), and for variants recently reported to cause
HTRA1 autosomal dominant forms of SVD (Verdura et al.,
2015).
Data availability
The data that support the findings of this study are available
from the corresponding author, upon reasonable request.
Results
The approach for defining the composite extreme pheno-
type of SVD (extreme SVD) is schematically presented in
Fig. 1. From a total sample of 1497 participants with MRI
and genome-wide genotype information within the 3C-
Dijon study, 514 participants (261 with extensive SVD
and 253 with minimal SVD) were identified.
Characteristics of 3C-Dijon participants with extreme
SVD are described in Table 1. Participants with extensive
and minimal SVD had similar age and gender distributions.
Participants with extensive SVD had more vascular risk
factors than those with minimal SVD, the most significant
association being observed for hypertension. Compared to
participants with minimal SVD, those with extensive SVD
were more often current smokers, and had more frequently
a history of cardiovascular disease, as well as higher fasting
plasma glucose, triglycerides, and BMI, but lower LDL-
cholesterol (Table 1). Over the mean follow-up period of
9.2  2.7 years, 40 participants were diagnosed with de-
mentia, and 20 with stroke. Compared to participants
with minimal SVD, those with extensive SVD showed a
significantly increased risk of developing incident dementia
[hazard ratio (HR) (95% confidence interval, CI) = 1.94
(1.01–3.73), P = 0.05] and a trend towards an increased
risk of incident stroke [HR (95%CI) = 2.54 (0.95–6.74),
P = 0.06]. Characteristics of replication studies with ex-
treme-SVD are described in Supplementary Tables 1 and 2.
Single variant association analyses identified a significant as-
sociation of an intronic variant in HTRA1 (rs2293871-T, fre-
quency = 0.19) with extreme SVD (Table 2). This association
was significant after correcting for multiple testing
Table 1 Baseline characteristics of 3C-Dijon participants with extreme cerebral SVD
Characteristics Extensive SVD Minimal SVD P-value*
Participants, n 259 253 NA
WMH volume, ml, mean  SD 13.18  7.07 2.05  0.63 50.0001
Presence of lacunes, n (%) 58 (22.4) 0 NA
Age at MRI, years, mean  SD 73.5  4.01 73.19  4.45 0.4
Female, n (%) 150 (58.1) 155 (61) 0.51
Hypertension, n (%)a 223 (86.4) 184 (72.4) 50.0001
Systolic BP, mmHg, mean  SD 152.05  22.51 147.07  21.85 0.011
Antihypertensive drug intake, n (%) 146 (56.6) 93 (36.6) 50.0001
Fasting plasma glucose, mmol/l, mean  SD 5.18  1.51 4.95  0.67 0.026
Diabetes mellitus, n (%)b 25 (9.7) 14 (5.5) 0.07
HDL cholesterol, mmol/l, mean  SD 1.64  0.39 1.68  0.41 0.23
LDL cholesterol, mmol/l, mean  SD 3.53  0.89 3.68  0.84 0.046
TG, mmol/l, mean  SD 1.26  0.56 1.15  0.52 0.031
Lipid lowering drug, n (%) 96 (37.2) 71 (28) 0.026
BMI, kg/m2, mean  SD 25.84  3.92 24.86  3.71 0.004
Current smoker, n (%) 22 (8.5) 8 (3.1) 0.012
History of CVD at MRI, n (%)c 15 (5.8) 5 (2) 0.025
Hypercholesterolaemia, n (%)d 142 (55) 140 (55.3) 0.95
*Significant differences across SVD status obtained from analysis of covariance (continuous variables) or chi-square tests (categorical variables). Models with WMH volume as the
dependent variable are adjusted for intracranial volume.
aSystolic blood pressure 5140 mmHg, or diastolic blood pressure 590 mmHg, or use of antihypertensive drugs.
bFasting blood glucose 57 mmol/l or antidiabetic drug intake.
cHistory of myocardial infarction, bypass cardiac surgery, angioplasty, or peripheral artery disease.
dHypercholesterolaemia was defined as fasting total cholesterol 56.2 mmol/l or use of any lipid-lowering drug (fibrates, statins or bile acid sequestrant).
BMI = body mass index; BP = blood pressure; CVD = cardiovascular diseases; HDL = high-density lipoprotein; LDL = low-density lipoprotein; TG = triglycerides.
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(permutation derived 95% empirical significance threshold
P5 2.89  104, Supplementary material, part A) and re-
mained significant after additionally adjusting for hypertension
status (Table 2). Moreover the top-SNP locus-based test imple-
mented in the VEGAS2 software (Mishra and Macgregor,
2015) confirmed that the association of rs2293871 with ex-
treme SVD is independent of the regional properties of the
HTRA1 locus: the linkage disequilibrium structure or number
of variants in the region (Table 2). The effect estimates of
rs2293871-Tappeared largerwhencomparing the58extensive
SVD participants with lacunes to minimal SVD participants
[OR (95%CI) = 3.04 (1.67–5.50), P = 2.56  104] than
when comparing the 203participantswith extensive SVDwith-
out lacunes to minimal SVD participants [OR (95%CI) = 1.80
(1.27–2.56), P = 9.60  104]. We replicated the association
of rs2293871 in independent cohorts of European ancestry (n
extreme SVD = 3308) using genome-wide genotype data for
this common intronic variant (Table 2). The association of
rs2293871 was not significant in the only African ancestry
sample (rs2293871-T frequency = 0.14, Supplementary
Table 3). The inverse variance weighted meta-analysis of dis-
covery and replication cohorts of Europeanancestry showedan
association of rs2293871-T with extensive SVD at an OR
(95%CI) of 1.29 (1.14–1.46), P = 4.72  105 (Table 2). The
same allele at rs2293871 was also associated with increased
risk of small vessel ischaemic stroke defined using the CCS
system in 16851 cases and 31259 controls in the NINDS-
SiGN study [NINDS Stroke Genetics Network (SiGN) and
International Stroke Genetics Consortium (ISGC), 2016]: OR
(95%CI) = 1.12 (1.03–1.22), P = 6.14  103 for causative
CCS and OR (95%CI) = 1.12 (1.04–1.22), P = 4.68  103
for phenotypic CCS. The rs2293871 variant showed nominal
association with continuous WMH burden (n = 17936, P-
value = 0.03) in a previously reported GWAS meta-analysis
(Verhaaren et al., 2015). Functional explorations using
HaploReg (Ward and Kellis, 2012) suggest that rs2293871
lies in the H3K9ac promoter and H3K4me1, H3K4me3 and
H3K27ac enhancer histone marks (Supplementary Table 4).
Two proxies of rs2293871 (rs876790 and rs2736928,
r2 = 0.75 with rs2293871) are eQTL for HTRA1 in blood
(Westra et al., 2013), with C alleles at rs876790 and
rs2736928 (in phase with rs2293871-T) showing significant
associationwith lowerHTRA1 transcript levels (false discovery
rate-corrected P-value = 0.03 and 0.04, respectively).
We analysed the association of protein-modifying (splice
acceptor variant, splice donor variant, start lost, stop lost,
stop gained, frameshift variant, inframe insertion, inframe
deletion, and missense variants only) rare and low fre-
quency variants (MAF50.05) in candidate genes using
the SKAT-O approach (Lee et al., 2012). Only three
genes NOTCH3, COL4A1, and COL4A2, satisfied the
criteria of cumulative MAF of protein-modifying rare or
low frequency variants of 41% (Supplementary Table 5),
thus qualifying for gene-based analyses. The SKAT-O gene-
based analysis identified a significant association of protein-
modifying rare and low frequency variants in the
NOTCH3 gene with extreme SVD (SKAT-OT
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P = 1.61  102, n extreme SVD = 512, Table 3), which
remain associated after additionally adjusting for hyperten-
sion status (SKAT-O P = 1.58  102, Table 3). We suc-
cessfully replicated the gene-based association of protein-
modifying rare and low-frequency variants in NOTCH3
with extreme SVD in four independent cohorts of
European ancestry (n extreme SVD = 956): SKAT-O
P = 3.99  102 for the replication set and SKAT-O
P = 5.31  103 for the combined discovery and replication
samples (Table 3). The NOTCH3 association was not sig-
nificant in the African ancestry sample of 242 extreme-SVD
participants (SKAT-O P = 0.78). Follow-up in a previously
described Sanger sequencing subset of the ASPS (Schmidt
et al., 2011) did not show any significant association in a
cohort of 171 participants with either coalescent white
matter lesions or lacunes compared with 82 randomly se-
lected participants with no focal changes on magnetic res-
onance images (SKAT-O P = 0.53), possibly due to limited
sample size.
Further exploratory protein-domain specific SKAT-O
analyses showed significant association of extreme SVD
with the EGFr domain determining region of the
NOTCH3 gene, which is known to preferentially harbour
mutations causing CADASIL (SKAT-O P = 2.14  102 for
3C-Dijon, SKAT-O P = 3.30  102 for the replication
samples, and SKAT-O P = 4.98  103 for the combined
discovery and replication). We also observed, in the 3C-
Dijon extreme SVD sample, that five of the missense vari-
ants in the EGFr determining region (T328I, S497L, S502F,
T759S, and S931G) were predicted mucin type GalNAc O-
glycosylation sites with predication scores ranging between
0.18 and 0.82 (Supplementary Table 6). The S502F, T759S
and S931G variants were observed exclusively in the 3C-
Dijon extensive-SVD sample (Fig. 2).
Screening of 3C-Dijon extreme SVD participants for rare
alleles at pathogenic or likely pathogenic variants in five
candidate genes harbouring mutations causing
monogenic SVD, identified two such alleles in the
NOTCH3 and HTRA1 genes. One extensive SVD partici-
pant carried a heterozygote genotype at a NOTCH3
EGFr domain cysteine altering variant: NM_000435.2
(NOTCH3):c.C2353T:p.R785C (Fig. 2) (participant level
depth coverage = 33 and Phred scaled genotype qual-
ity = 99, note: Phred score vary from 0 to 99 and 99 rep-
resents the highest Phred scaled confidence for genotype
quality). This variant leads to addition of a seventh cysteine
residue in EGF repeat 20 of the NOTCH3 N-terminus,
typical of CADASIL, and was previously described in
one Italian CADASIL family with an autosomal
dominant inheritance pattern (Mosca et al., 2014).
Another extensive SVD participant carried a heterozygote
genotype at the CARASIL-causing variant: NM_002775.4
(HTRA1):c.1108C4T (p.Arg370Ter), a nonsense variant
resulting in a stop codon at amino acid position 370 (par-
ticipant level depth coverage = 96 and Phred scaled geno-
type quality = 99). Only the homozygous TT genotype at
this variant has been reported to cause CARASIL in theT
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literature, in Asian populations (Hara et al., 2009). This
variant was not included in the list of variants reported
to cause a dominant HTRA1-related SVD phenotype in
Europeans (Verdura et al., 2015). Brain imaging character-
istics of both participants are shown in Fig. 3. Neither of
them had typical imaging features of CADASIL or
CARASIL at baseline, but the participant with a
NOTCH3 EGFr domain cysteine altering genotype de-
veloped WMH in the anterior temporal lobe, a location
typical for CADASIL, on a 4-year follow-up MRI scan.
Both participants were free of stroke and dementia.
We also observed two minimal-SVD participants carrying
a heterozygote genotype at one glycine residue altering mis-
sense variant in COL4A1 [NM_001845.4 (COL4A1):
c.3158G4A (p.Gly1053Asp), participant level depth
coverage = 125 and Phred scaled genotype quality = 99],
and one nonsense (stop gained) variant in COL4A2
[NM_001846.2 (COL4A2) c.3766C4T (p.Arg1256Ter),
participant level depth coverage = 77 and Phred scaled
genotype quality = 99]. Heterozygous glycine residue
changes and nonsense mutations in COL4A1 and
COL4A2 are typically described in SVD families with cere-
bral bleedings, although, to our knowledge, these specific
variants have not been described previously in any SVD
family. All protein-modifying variants observed in 3C-
Dijon participants with extreme-SVD within the five candi-
date genes are displayed in Fig. 2 (NOTCH3) and
Supplementary Fig. 2–5 (HTRA1, COL4A1, COL4A2
and TREX1).
Discussion
We report a novel gene-mapping strategy for SVD in popu-
lation-based cohorts of older person with MRI-defined ex-
tremes of SVD severity. We explored the association with
extreme SVD in the general population of common and
rare variants in five genes known to harbour mutations
causing Mendelian SVD, with a discovery sample of 512
participants and a follow-up sample of 3698 participants
for common variants and n = 1198 for rare and low fre-
quency variants. We report significant association of a
Figure 3 MRI images of participants carrying heterozygote genotypes at CADASIL and CARASIL causing mutations.
(A) Baseline (1) and 4-year follow-up (2) MRI scans of a 65-year old female participant with extensive SVD, in whom a NOTCH3 EGFr domain
cysteine-modifying mutation was found: NM_000435.2 (NOTCH3):c.C2353T:p.R785C. Images show lacunar infarcts and dilated perivascular
spaces in basal ganglia and white matter, and WMH in the periventricular region and deep white matter; on the follow-up MRI scan WMH and
dilated perivascular spaces burden had increased and WMH became visible in the anterior temporal lobes (yellow arrows), a typical location for
CADASIL. This participant remained free of stroke and dementia until the end of her follow-up at age 77. Her MMSE score was 28 at baseline and
26 at 12 years follow-up (secondary school education but no high school). (B) Baseline MRI scan of a 74-year-old female participant with extensive
SVD, in whom a heterozygous CARASIL causing mutation was found: NM_002775.4 (HTRA1):c.1108C4T (p.Arg370Ter). Images show WMH
and lacunes in the pons and extensive WMH in the deep white matter and periventricular region (magenta arrows). This participant was free of
stroke and dementia at baseline but was lost to follow-up. Her baseline MMSE score was 27 (primary school education).
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common intronic variant in the HTRA1 gene with extreme
SVD, with evidence suggesting that the risk allele is low-
ering HTRA1 expression. We also found a significant as-
sociation with extreme SVD of rare and low frequency
NOTCH3 protein-modifying variants using a gene-based
approach. Finally, in 512 participants from the 3C-Dijon
discovery population-based sample, we also screened for
pathogenic variants causing Mendelian SVD and identified
two participants with extensive SVD harbouring heterozy-
gote genotypes for such variants in NOTCH3 (CADASIL-
causing missense variant modifying a cysteine-residue of the
EGFR domain) and in HTRA1 (heterozygous carrier of a
CARASIL causing mutation).
Our novel approach complements the gene-mapping stra-
tegies traditionally being used to identify SVD risk loci in
population-based cohorts, consisting of studying each MRI-
marker of SVD individually: presence or absence of brain
infarct (Debette et al., 2010) and, quantitative measure of
WMH burden (Verhaaren et al., 2015), and of efforts to
reveal genetic determinants of the clinically defined small
vessel ischaemic stroke subtype [NINDS Stroke Genetics
Network (SiGN) and International Stroke Genetics
Consortium (ISGC), 2016]. The extreme composite pheno-
type of SVD presented here is likely to be more specific for
underlying SVD pathology and provides a better contrast
by excluding participants with either lacunes or moderate
to extensive WMH burden from the control group.
Extreme phenotype association studies have been reported
to be better powered for identifying rare risk variants asso-
ciated with disease by reducing the phenotypic heterogen-
eity (Peloso et al., 2016), which we demonstrate through
association of rare and low frequency NOTCH3 protein-
modifying variants with extreme-SVD. Notably, we also
demonstrate that our study design is more powerful to
identify some common SVD risk variants, as the common
intronic variant rs2293871 in HTRA1 has greater signifi-
cance in relation with extreme SVD compared to associ-
ations observed with small vessel ischaemic stroke
[NINDS Stroke Genetics Network (SiGN) and
International Stroke Genetics Consortium (ISGC), 2016]
and continuous WMH burden (Verhaaren et al., 2015),
which had comparatively more number of participants
than the former study. This observation is in line with
simulation studies demonstrating that extreme sample phe-
notyping might identify additional common risk variants
(MAF4 0.05) associated with complex diseases by redu-
cing the impact of phenotype misclassification on observed
genetic effect size estimates (van der Sluis et al., 2010;
Manchia et al., 2013).
We report and replicate an association of a common in-
tronic variant (rs2293871) in HTRA1 with extreme-SVD in
European ancestry cohorts. HTRA1 encodes a secretory
protein of the serine protease family, which regulates trans-
forming growth factor (TGF) signalling (Beaufort et al.,
2014). Disruption in HTRA1 activity causing cell death
by modulating TGF signalling has been suggested as a pos-
sible causal mechanism underlying CARASIL (Beaufort
et al., 2014). We identified two blood eQTLs in linkage
disequilibrium (r2 = 0.75) with rs2293871, suggesting that
the allele associated with increased risk of extensive SVD is
associated with lower HTRA1 expression in blood.
Although limited to blood, and based on proxies in mod-
erate linkage disequilibrium, this observation is in line with
suggested mechanisms of reduced HTRA1 activity in
CARASIL (Hara et al., 2009; Beaufort et al., 2014), and
also the recent description of heterozygote loss-of-function
variants in HTRA1 causing SVD phenotypes in European
populations (Verdura et al., 2015).
Using a gene-based approach we also demonstrate signifi-
cant association with extreme SVD of NOTCH3 protein-
modifying rare and low frequency variants, which were
replicated in independent cohorts. This association is pri-
marily driven by variants located in the EGFr domain,
known to preferentially harbour CADASIL causing muta-
tions. CADASIL, the most common of all known
Mendelian forms of SVD, is an autosomal dominant dis-
ease typically caused by cysteine residue altering variants in
NOTCH3 resulting in an uneven number of cysteines in
the EGFr domain of NOTCH3, disrupting disulphide
bridge formation, causing misfolding of EGFr, and increas-
ing NOTCH3 multimerization (Monet-Lepretre et al.,
2013). Some cysteine-modifying mutational hotspots
(R91C, R170C or C213S) were reported to cause aberrant
dimerization of NOTCH3 fragments by reducing Fringe-
mediated elongation of O-fucose glycosylation (Arboleda-
Velasquez et al., 2005). In rare instances, cysteine-sparing
variants were also reported to cause CADASIL in some
families, but their pathogenicity is still debated. Five mis-
sense variants in EGFr determining region observed in the
3C-Dijon extreme SVD sample are predicted mucin type
GalNAc O-glycosylation sites, of which three variants
were exclusively observed in participants with extensive
SVD. Because of the lack of publicly available resources
to computationally predict other types of O-glycosylation
than mucin (O-fucose, O-glucose, O-GlcNAc, and O-
xylose) we have only partially captured the impact of
observed NOTCH3 missense variants on glycosylation dis-
ruption in the EGFr domain. Further functional studies are
essential to understand the impact of glycosylation disrup-
tion in the EGFr domain of NOTCH3 by genetic variants
in complex SVD pathophysiology.
Interestingly, two participants with extensive SVD, repre-
senting 0.4% of our discovery population-based sample,
and 0.8% of participants with extensive SVD, carried het-
erozygous mutations in NOTCH3 or HTRA1 described
previously as pathogenic and causing CADASIL or
CARASIL, two Mendelian forms of SVD. Of note, this
observation is based on high quality WES data but lacks
technical validation using targeted Sanger sequencing. The
frequency of known pathogenic variants in our community
sample is higher than expected, but in line with a recent
analysis of NOTCH3 likely pathogenic variants described
in 0.3% of the 60,706 exomes of the publicly available
exome aggregation consortium (ExAC) database (Rutten
Exome sequencing study on MRI-defined extremes of SVD BRAIN 2019: 142; 1009–1023 | 1019
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/4/1009/5374837 by guest on 01 July 2020
et al., 2016a). The main shortcoming of the ExAC database
is the limited clinical information on participants included
in the database and the lack of data on covert, MRI-defined
SVD phenotypes. Our study provides further evidence that
pathogenic variants known to cause rare Mendelian forms
of SVD (CADASIL and CARASIL) are less exceptional
than previously suspected in the general population.
Although they were observed in persons with extensive
SVD on brain imaging, they appeared to have mild clinical
expression in this population-based setting. The CADASIL
causing variant reported in our cohort modifies the cysteine
residue of the EGF repeat 20 of the NOTCH3 N-terminus.
Interestingly, cysteine modifying mutations at EGF repeats
7–34 may have a milder CADASIL phenotype than those
affecting EGFr domain 1–6 at the C-terminal end, because
of lower likelihood of interaction of unpaired cysteine with
other proteins (Rutten et al., 2016a). Our results further
add to the debate around returning results on incidental
findings from next generation sequencing considering that
the penetrance of likely pathogenic variants may be highly
variable (Hehir-Kwa et al., 2015; Hofmann, 2016).
Intriguingly we observed two missense variants in
COL4A1 and COL4A2 in 3C-Dijon participants with min-
imal SVD, with typical characteristics of SVD causing mu-
tations, although they have not been described previously
in SVD families. This may reflect low penetrance. Indeed,
clinical studies have shown that a significant proportion of
mutation carriers do not develop intracerebral bleedings
(Meuwissen et al., 2015). This may also be explained by
the fact that our brain imaging protocol did not include
gradient echo images to detect previous microbleeds or
intracerebral haemorrhages, as the most common manifest-
ations of COL4A1/2 related SVD are brain haemorrhages
(Lanfranconi and Markus, 2010).
Our proof-of-concept gene-mapping study focused on
genetic variants within five candidate genes observed
using the WES technique. One notable limitation of this
work is that it did not report on association of some
common risk variants relevant to SVD pathology that
were identified using the GWAS approach, as these were
not captured by WES, particularly COL4A2 intronic vari-
ants, respectively, rs9515201, rs9521732, rs9521733, and
rs9515199, which were recently reported to be associated
with WMH volume (Traylor et al., 2016) and deep intra-
cerebral haemorrhage (Rannikmae et al., 2015).
Furthermore, as we focused only on SVD candidate
genes, our study did not explore the impact on extreme
SVD of rare and common variants in other candidate
loci, such as those previously associated with continuous
WMH burden (Verhaaren et al., 2015; Traylor et al.,
2016), stroke (Malik et al., 2018) or Alzheimer’s disease
(Lambert et al., 2013). These limitations will need to be
addressed through a large multi-cohort gene-mapping
study using GWAS and possibly whole genome sequencing
approaches.
In summary, our proof-of-concept study provides strong
evidence that using a novel composite MRI-derived
phenotype for extremes of SVD can facilitate the identifi-
cation of genetic variants underlying SVD, both common
variants and those with rare and low frequency. The find-
ings demonstrate shared mechanisms and a continuum be-
tween genes underlying Mendelian SVD and those
contributing to the common, multifactorial form of the dis-
ease. Future studies exploring rare and common genetic
variants associated with this composite extreme SVD
phenotype at a genome-wide or whole genome level are
warranted. Indeed, SVD is a major contributor to stroke
and dementia risk worldwide with no specific therapy avail-
able to date, and efforts to decipher underlying biological
pathways to accelerate the discovery of novel treatment
strategies represent a public health priority.
Acknowledgements
We thank Dr Anne Boland (CNG) for her technical help in
preparing the DNA samples for analyses. We thank Pascal
Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and
Marjolein Peters, and Carolina Medina-Gomez, for their
help in creating the GWAS database, and Karol Estrada,
Yurii Aulchenko, and Carolina Medina-Gomez, for the
creation and analysis of imputed data. The generation
and management of the exome sequencing data for the
Rotterdam Study was executed by the Human
Genotyping Facility of the Genetic Laboratory of the
Department of Internal Medicine, Erasmus MC, the
Netherlands. We thank Pascal Arp, Mila Jhamai, Jeroen
van Rooij, Marijn Verkerk, and Robert Kraaij for their
help in creating the RS-Exome Sequencing database. The
authors are grateful to the study participants, the staff from
the Rotterdam Study and the participating general practi-
tioners and pharmacists.
Funding
This project is supported by the Fondation Leducq
(Transatlantic Network of Excellence on the Pathogenesis
of SVD of the Brain) and is an EU Joint Programme -
Neurodegenerative Disease Research (JPND) project. The
project is supported through the following funding organ-
isations under the aegis of JPND www.jpnd.eu: Australia,
National Health and Medical Research Council, Austria,
Federal Ministry of Science, Research and Economy;
Canada, Canadian Institutes of Health Research; France,
French National Research Agency; Germany, Federal
Ministry of Education and Research; Netherlands, The
Netherlands Organisation for Health Research and
Development; United Kingdom, Medical Research
Council. This project has received funding from the
European Union’s Horizon 2020 research and innovation
programme under grant agreement No 643417. This pro-
ject has also received funding from the European Research
Council (ERC) under the European Union’s Horizon 2020
1020 | BRAIN 2019: 142; 1009–1023 A. Mishra et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/4/1009/5374837 by guest on 01 July 2020
research and innovation programme under grant agreement
No 640643. This project has received funding from
European Union’s Horizon 2020 research and innovation
programme under grant agreement No 667375.
Computations were performed on the Bordeaux
Bioinformatics Center (CBiB) computer resources,
Universite´ de Bordeaux. Funding support for additional
computer resources has been provided to S.D. by the
Fondation Claude Pompidou.
The Three City Study: The Three City (3C) Study is con-
ducted under a partnership agreement among the Institut
National de la Sante´ et de la Recherche Me´dicale
(INSERM), the University of Bordeaux, and Sanofi-
Aventis. The Fondation pour la Recherche Me´dicale
funded the preparation and initiation of the study. The
3C Study is also supported by the Caisse Nationale
Maladie des Travailleurs Salarie´s, Direction Ge´ne´rale de
la Sante´, Mutuelle Ge´ne´rale de l’Education Nationale
(MGEN), Institut de la Longe´vite´, Conseils Re´gionaux of
Aquitaine and Bourgogne, Fondation de France, and
Ministry of Research–INSERM Programme ‘Cohortes et
collections de donne´es biologiques.’ C.T. and S.D. have
received investigator-initiated research funding from the
French National Research Agency (OPE-2016-0500) and
from the Fondation Leducq (12CVD01). This work was
supported by the National Foundation for Alzheimer’s dis-
ease and related disorders, the Institut Pasteur de Lille, the
Centre National de Ge´notypage, the French government’s
LABEX (laboratory of excellence program investment for
the future) DISTALZ grant (Development of Innovative
Strategies for a Transdisciplinary approach to Alzheimer’s
disease), and the GENMED labex.
The Atherosclerosis Risk in Communities study: The
Atherosclerosis Risk in Communities study (ARIC) was
performed as a collaborative study supported by National
Heart, Lung, and Blood Institute (NHLBI) contracts
(HHSN268201100005C, HSN268201100006C, HSN26
8201100007C, HHSN268201100008C, HHSN2682011
00009C, HHSN268201100010C, HHSN268201100011C,
and HHSN268201100012C), R01HL70825, R01HL087
641, R01HL59367, and R01HL086694; National Human
Genome Research Institute contract U01HG004402;
and National Institutes of Health (NIH) contract
HHSN268200625226C. Infrastructure was partly sup-
ported by grant No. UL1RR025005, a component of the
NIH and NIH Roadmap for Medical Research. This pro-
ject was also supported by NIH R01 grant NS087541 to
M.F.
The Cardiovascular Health Study: The Cardiovascular
Health study (CHS) research was supported by contracts
HHSN268201200036C, HHSN268200800007C, HHSN
268201800001C, N01HC55222, N01HC85079, N01HC
85080, N01HC85081, N01HC85082, N01HC85083,
N01HC85086, N01HC15103, and HHSN2682009
60009C and grants U01HL080295, R01HL087652,
R01HL105756, R01HL103612, R01HL120393, R01HL
085251, and U01HL130114 from the National Heart,
Lung, and Blood Institute (NHLBI) with additional contri-
bution from the National Institute of Neurological
Disorders and Stroke (NINDS). Additional support was
provided through R01AG023629 and R01AG033193
from the National Institute on Aging (NIA). A full list of
principal CHS investigators and institutions can be found
at chs-nhlbi.org. The provision of genotyping data was sup-
ported in part by the National Center for Advancing
Translational Sciences, CTSI grant UL1TR001881, and
the National Institute of Diabetes and Digestive and
Kidney Disease Diabetes Research Center (DRC) grant
DK063491 to the Southern California Diabetes
Endocrinology Research Center. The content is solely the
responsibility of the authors and does not necessarily rep-
resent the official views of the National Institutes of Health.
Funding support for ‘Building on GWAS for NHLBI-dis-
eases: the U.S. CHARGE Consortium’ was provided by the
NIH through the American Recovery and Reinvestment Act
of 2009 (ARRA) (5RC2HL102419). Data for ‘Building on
GWAS for NHLBI-diseases: the U.S. CHARGE
Consortium’ were provided by Eric Boerwinkle on behalf
of the Atherosclerosis Risk in Communities (ARIC) Study,
L. Adrienne Cupples, principal investigator for the
Framingham Heart Study, and Bruce Psaty, principal inves-
tigator for the Cardiovascular Health Study. Sequencing
was carried out at the Baylor Genome Center (U54
HG003273).
The Framingham Heart Study (FHS): This work was sup-
ported by the National Heart, Lung and Blood Institute’s
Framingham Heart Study (Contracts No. N01-HC-25195
and No. HHSN268201500001I), and its contract with
Affymetrix, Inc. for genotyping services (Contract No. N02-
HL-6–4278). A portion of this research utilized the Linux
Cluster for Genetic Analysis (LinGA-II) funded by the Robert
Dawson Evans Endowment of the Department of Medicine at
Boston University School of Medicine and Boston Medical
Center. This study was also supported by grants from the
National Institute of Aging (R01s AG033040, AG033193,
AG054076, AG049607, AG008122, and U01-AG049505)
and the National Institute of Neurological Disorders and
Stroke (R01-NS017950, UH2 NS100605).
The Rotterdam Study: The generation and management
of GWAS genotype data for the Rotterdam Study (RS I, RS
II, RS III) was executed by the Human Genotyping Facility
of the Genetic Laboratory of the Department of Internal
Medicine, Erasmus MC, Rotterdam, The Netherlands. The
GWAS datasets are supported by the Netherlands
Organisation of Scientific Research NWO Investments (nr.
175.010.2005.011, 911–03–012), the Genetic Laboratory
of the Department of Internal Medicine, Erasmus MC,
the Research Institute for Diseases in the Elderly (014–
93–015; RIDE2), the Netherlands Genomics Initiative
(NGI)/Netherlands Organisation for Scientific Research
(NWO) Netherlands Consortium for Healthy Aging
(NCHA), project nr. 050–060–810. The Exome
Sequencing dataset was funded by the Netherlands
Genomics Initiative (NGI)/Netherlands Organisation for
Exome sequencing study on MRI-defined extremes of SVD BRAIN 2019: 142; 1009–1023 | 1021
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/4/1009/5374837 by guest on 01 July 2020
Scientific Research (NWO) sponsored Netherlands
Consortium for Healthy Aging (NCHA; project nr.
050–060–810), by the Genetic Laboratory of the
Department of Internal Medicine, Erasmus MC, and by
the and by a Complementation Project of the Biobanking
and Biomolecular Research Infrastructure Netherlands
(BBMRI-NL; www.bbmri.nl; project number CP2010–41).
The Rotterdam Study is funded by Erasmus Medical Center
and Erasmus University, Rotterdam, Netherlands
Organization for the Health Research and Development
(ZonMw), the Research Institute for Diseases in the
Elderly (RIDE), the Ministry of Education, Culture and
Science, the Ministry for Health, Welfare and Sports, the
European Commission (DG XII), and the Municipality of
Rotterdam.
The Austrian Stroke Prevention Study (ASPS): The re-
search reported in this article was funded by the Austrian
Science Fund (FWF) grant number P20545-P05, P13180
and P20545-B05, by the Austrian National Bank
Anniversary Fund, P15435, and the Austrian Ministry of
Science under the aegis of the EU Joint Programme -
Neurodegenerative Disease Research (JPND) www.jpnd.eu
received funding from the European Union’s Horizon 2020
research and innovation programme under grant agreement
No 643417.
Competing interests
The authors report no competing interests.
Supplementary material
Supplementary material is available at Brain online.
References
C Study Group. Vascular factors and risk of dementia: design of the
Three-City Study and baseline characteristics of the study popula-
tion. Neuroepidemiology 2003; 22: 316–25.
Arboleda-Velasquez JF, Rampal R, Fung E, Darland DC, Liu M,
Martinez MC, et al. CADASIL mutations impair Notch3 glycosyla-
tion by Fringe. Hum Mol Genet 2005; 14: 1631–9.
Beaufort N, Scharrer E, Kremmer E, Lux V, Ehrmann M, Huber R,
et al. Cerebral small vessel disease-related protease HtrA1 processes
latent TGF-beta binding protein 1 and facilitates TGF-beta signaling.
Proc Natl Acad Sci USA 2014; 111: 16496–501.
Bellenguez C, Charbonnier C, Grenier-Boley B, Quenez O, Le Guennec
K, Nicolas G, et al. Contribution to Alzheimer’s disease risk of rare
variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273
controls. Neurobiol Aging 2017; 59: 220.e1–e9.
Boskovski MT, Yuan S, Pedersen NB, Goth CK, Makova S, Clausen
H, et al. The heterotaxy gene GALNT11 glycosylates Notch to or-
chestrate cilia type and laterality. Nature 2013; 504: 456–9.
Crawford KM, Gallego-Fabrega C, Kourkoulis C, Miyares L, Marini
S, Flannick J, et al. Cerebrovascular disease knowledge portal: an
open-access data resource to accelerate genomic discoveries in
stroke. Stroke 2018; 49: 470–5.
Cruchaga C, Karch CM, Jin SC, Benitez BA, Cai Y, Guerreiro R, et al.
Rare coding variants in the phospholipase D3 gene confer risk for
Alzheimer’s disease. Nature 2014; 505: 550–4.
Debette S, Bis JC, Fornage M, Schmidt H, Ikram MA, Sigurdsson S,
et al. Genome-wide association studies of MRI-defined brain in-
farcts: meta-analysis from the CHARGE Consortium. Stroke 2010;
41: 210–7.
DeStefano AL, Seshadri S, Beiser A, Atwood LD, Massaro JM, Au R,
et al. Bivariate heritability of total and regional brain volumes: the
Framingham Study. Alzheimer Dis Assoc Disord 2009; 23: 218–23.
Fornage M, Debette S, Bis JC, Schmidt H, Ikram MA, Dufouil C, et al.
Genome-wide association studies of cerebral white matter lesion
burden: the CHARGE consortium. Ann Neurol 2011; 69: 928–39.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concen-
tration of low-density lipoprotein cholesterol in plasma, without use
of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V,
Gaulton KJ, et al. The genetic architecture of type 2 diabetes. Nature
2016; 536: 41–7.
Gunda B, Mine M, Kovacs T, Hornyak C, Bereczki D, Varallyay G,
et al. COL4A2 mutation causing adult onset recurrent intracerebral
hemorrhage and leukoencephalopathy. J Neurol 2014; 261: 500–3.
Hara K, Shiga A, Fukutake T, Nozaki H, Miyashita A, Yokoseki A,
et al. Association of HTRA1 mutations and familial ischaemic cere-
bral small-vessel disease. N Engl J Med 2009; 360: 1729–39.
Hehir-Kwa JY, Claustres M, Hastings RJ, van Ravenswaaij-Arts C,
Christenhusz G, Genuardi M, et al. Towards a European consensus
for reporting incidental findings during clinical NGS testing. Eur
J Hum Genet 2015; 23: 1601–6.
Hofmann B. Incidental findings of uncertain significance: to know or
not to know–that is not the question. BMC Med Ethics 2016; 17:
13.
Joutel A, Vahedi K, Corpechot C, Troesch A, Chabriat H, Vayssiere
C, et al. Strong clustering and stereotyped nature of Notch3 muta-
tions in CADASIL patients. Lancet 1997; 350: 1511–5.
Kaffashian S, Tzourio C, Soumare A, Dufouil C, Zhu Y, Crivello F,
et al. Plasma beta-amyloid and MRI markers of cerebral small vessel
disease: three-city Dijon study. Neurology 2014; 83: 2038–45.
Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R,
Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies
11 new susceptibility loci for Alzheimer’s disease. Nat Genet
2013; 45: 1452–8.
Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S,
et al. ClinVar: public archive of interpretations of clinically relevant
variants. Nucleic Acids Res 2016; 44: D862–8.
Lanfranconi S, Markus HS. COL4A1 mutations as a monogenic cause
of cerebral small vessel disease: a systematic review. Stroke 2010;
41: e513–8.
Lange LA, Hu Y, Zhang H, Xue C, Schmidt EM, Tang ZZ, et al.
Whole-exome sequencing identifies rare and low-frequency coding
variants associated with LDL cholesterol. Am J Hum Genet 2014;
94: 233–45.
Lee S, Wu MC, Lin X. Optimal tests for rare variant effects in sequen-
cing association studies. Biostatistics 2012; 13: 762–75.
Li H, Durbin R. Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 2009; 25: 1754–60.
Longstreth WT, Jr. Brain vascular disease overt and covert. Stroke
2005; 36: 2062–3.
Maillard P, Delcroix N, Crivello F, Dufouil C, Gicquel S, Joliot M,
et al. An automated procedure for the assessment of white matter
hyperintensities by multispectral (T1, T2, PD) MRI and an evalu-
ation of its between-centre reproducibility based on two large com-
munity databases. Neuroradiology 2008; 50: 31–42.
Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y,
Mishra A, et al. Multiancestry genome-wide association study of
520,000 subjects identifies 32 loci associated with stroke and
stroke subtypes. Nat Genet 2018; 50: 524–37.
1022 | BRAIN 2019: 142; 1009–1023 A. Mishra et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/4/1009/5374837 by guest on 01 July 2020
Manchia M, Cullis J, Turecki G, Rouleau GA, Uher R, Alda M. The
impact of phenotypic and genetic heterogeneity on results of genome
wide association studies of complex diseases. PLoS One 2013; 8:
e76295.
Matsuura A, Ito M, Sakaidani Y, Kondo T, Murakami K, Furukawa
K, et al. O-linked N-acetylglucosamine is present on the extracellular
domain of notch receptors. J Biol Chem 2008; 283: 35486–95.
McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K,
Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce
framework for analyzing next-generation DNA sequencing data.
Genome Res 2010; 20: 1297–303.
McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GR, Thormann A, et al.
The ensembl variant effect predictor. Genome Biol 2016; 17: 122.
Mele M, Ferreira PG, Reverter F, DeLuca DS, Monlong J, Sammeth
M, et al. Human genomics. The human transcriptome across tissues
and individuals. Science 2015; 348: 660–5.
Meuwissen ME, Halley DJ, Smit LS, Lequin MH, Cobben JM, de Coo
R, et al. The expanding phenotype of COL4A1 and COL4A2 mu-
tations: clinical data on 13 newly identified families and a review of
the literature. Genet Med 2015; 17: 843–53.
Mishra A, Macgregor S. VEGAS2: Software for more flexible gene-
based testing. Twin Res Hum Genet 2015; 18: 86–91.
Moloney DJ, Shair LH, Lu FM, Xia J, Locke R, Matta KL, et al.
Mammalian Notch1 is modified with two unusual forms of O-
linked glycosylation found on epidermal growth factor-like modules.
J Biol Chem 2000; 275: 9604–11.
Monet-Lepretre M, Haddad I, Baron-Menguy C, Fouillot-Panchal M,
Riani M, Domenga-Denier V, et al. Abnormal recruitment of extra-
cellular matrix proteins by excess Notch3 ECD: a new pathome-
chanism in CADASIL. Brain 2013; 136 (Pt 6): 1830–45.
Mosca L, Rivieri F, Tanel R, Bonfante A, Burlina A, Manfredini E,
et al. Mutational screening of NOTCH3 gene reveals two novel
mutations: complexity of CADASIL diagnosis. J Mol Neurosci
2014; 54: 723–9.
NINDS Stroke Genetics Network (SiGN), International Stroke
Genetics Consortium (ISGC). Loci associated with ischaemic stroke
and its subtypes (SiGN): a genome-wide association study. Lancet
Neurol 2016; 15: 174–84.
Pantoni L. Cerebral small vessel disease: from pathogenesis and clin-
ical characteristics to therapeutic challenges. Lancet Neurol 2010; 9:
689–701.
Peloso GM, Rader DJ, Gabriel S, Kathiresan S, Daly MJ, Neale BM.
Phenotypic extremes in rare variant study designs. Eur J Hum Genet
2016; 24: 924–30.
Rannikmae K, Davies G, Thomson PA, Bevan S, Devan WJ, Falcone
GJ, et al. Common variation in COL4A1/COL4A2 is associated
with sporadic cerebral small vessel disease. Neurology 2015; 84:
918–26.
Richards A, van den Maagdenberg AM, Jen JC, Kavanagh D, Bertram
P, Spitzer D, et al. C-terminal truncations in human 3’-5’ DNA
exonuclease TREX1 cause autosomal dominant retinal vasculopathy
with cerebral leukodystrophy. Nat Genet 2007; 39: 1068–70.
Rutten JW, Dauwerse HG, Gravesteijn G, van Belzen MJ, van der
Grond J, Polke JM, et al. Archetypal NOTCH3 mutations frequent
in public exome: implications for CADASIL. Ann Clin Transl
Neurol 2016a; 3: 844–53.
Rutten JW, Dauwerse HG, Peters DJ, Goldfarb A, Venselaar H,
Haffner C, et al. Therapeutic NOTCH3 cysteine correction in
CADASIL using exon skipping: in vitro proof of concept. Brain
2016b; 139 (Pt 4): 1123–35.
Sachdev PS, Lee T, Wen W, Ames D, Batouli AH, Bowden J, et al. The
contribution of twins to the study of cognitive ageing and dementia:
the Older Australian Twins Study. Int Rev Psychiatry 2013; 25:
738–47.
Schilling S, Tzourio C, Soumare A, Kaffashian S, Dartigues JF, Ancelin
ML, et al. Differential associations of plasma lipids with incident
dementia and dementia subtypes in the 3C Study: a longitudinal,
population-based prospective cohort study. PLoS Med 2017; 14:
e1002265.
Schmidt H, Zeginigg M, Wiltgen M, Freudenberger P, Petrovic K,
Cavalieri M, et al. Genetic variants of the NOTCH3 gene in the
elderly and magnetic resonance imaging correlates of age-related
cerebral small vessel disease. Brain 2011; 134 (Pt 11): 3384–97.
Steentoft C, Vakhrushev SY, Joshi HJ, Kong Y, Vester-Christensen
MB, Schjoldager KT, et al. Precision mapping of the human O-
GalNAc glycoproteome through SimpleCell technology. EMBO J
2013; 32: 1478–88.
Stitziel NO, Peloso GM, Abifadel M, Cefalu AB, Fouchier S,
Motazacker MM, et al. Exome sequencing in suspected monogenic
dyslipidemias. Circ Cardiovasc Genet 2015; 8: 343–50.
Takeuchi H, Fernandez-Valdivia RC, Caswell DS, Nita-Lazar A, Rana
NA, Garner TP, et al. Rumi functions as both a protein O-glucosyl-
transferase and a protein O-xylosyltransferase. Proc Natl Acad Sci
USA 2011; 108: 16600–5.
The World Health Organization MONICA Project (monitoring trends
and determinants in cardiovascular disease): a major international
collaboration. WHO MONICA Project Principal Investigators. J
Clin Epidemiol 1988; 41: 105–14.
Traylor M, Bevan S, Baron JC, Hassan A, Lewis CM, Markus HS.
Genetic architecture of lacunar stroke. Stroke 2015; 46: 2407–12.
Traylor M, Zhang CR, Adib-Samii P, Devan WJ, Parsons OE,
Lanfranconi S, et al. Genome-wide meta-analysis of cerebral white
matter hyperintensities in patients with stroke. Neurology 2016; 86:
146–53.
Turner ST, Jack CR, Fornage M, Mosley TH, Boerwinkle E, de
Andrade M. Heritability of leukoaraiosis in hypertensive sibships.
Hypertension 2004; 43: 483–7.
Vahedi K, Boukobza M, Massin P, Gould DB, Tournier-Lasserve E,
Bousser MG. Clinical and brain MRI follow-up study of a family
with COL4A1 mutation. Neurology 2007; 69: 1564–8.
van der Sluis S, Verhage M, Posthuma D, Dolan CV. Phenotypic com-
plexity, measurement bias, and poor phenotypic resolution contrib-
ute to the missing heritability problem in genetic association studies.
PLoS One 2010; 5: e13929.
Verdura E, Herve D, Scharrer E, Amador Mdel M, Guyant-Marechal
L, Philippi A, et al. Heterozygous HTRA1 mutations are associated
with autosomal dominant cerebral small vessel disease. Brain 2015;
138 (Pt 8): 2347–58.
Verhaaren BF, Debette S, Bis JC, Smith JA, Ikram MK, Adams HH,
et al. Multiethnic genome-wide association study of cerebral white
matter hyperintensities on MRI. Circ Cardiovasc Genet 2015; 8:
398–409.
Ward linkage disequilibrium, Kellis M. HaploReg: a resource for
exploring chromatin states, conservation, and regulatory motif alter-
ations within sets of genetically linked variants. Nucleic Acids Res
2012; 40: D930–4.
Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne
R, et al. Neuroimaging standards for research into small vessel dis-
ease and its contribution to ageing and neurodegeneration. Lancet
Neurol 2013; 12: 822–38.
Westra HJ, Peters MJ, Esko T, Yaghootkar H, Schurmann C,
Kettunen J, et al. Systematic identification of trans eQTLs as puta-
tive drivers of known disease associations. Nat Genet 2013; 45:
1238–43.
Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-ana-
lysis of genomewide association scans. Bioinformatics 2010; 26:
2190–1.
Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant asso-
ciation testing for sequencing data with the sequence kernel associ-
ation test. Am J Hum Genet 2011; 89: 82–93.
Zhu YC, Tzourio C, Soumare A, Mazoyer B, Dufouil C, Chabriat H.
Severity of dilated Virchow-Robin spaces is associated with age,
blood pressure, and MRI markers of small vessel disease: a popula-
tion-based study. Stroke 2010; 41: 2483–90.
Exome sequencing study on MRI-defined extremes of SVD BRAIN 2019: 142; 1009–1023 | 1023
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/article-abstract/142/4/1009/5374837 by guest on 01 July 2020
